This is a working overview of BPC-157, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-26 and is reviewed periodically as new material appears.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized powder | Freeze-dried solid, often hygroscopic |
| Solubility class | Freely soluble in water | Aqueous buffers used for stock solutions |
| Storage, dry powder | Minus 20 °C or colder | Recommended for long-term retention |
| Storage, solution | 2–8 °C or frozen | Avoid repeated freeze-thaw cycles |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity percentage plus mass confirmation |
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
This is the issue of color rendition, quite separate from color temperature. An orange or cyan object could appear with the wrong color and much darker as the LED or phosphor does not emit the wavelength it reflects. The best color rendition LEDs use a mix of phosphors, resulting in less efficiency and better color rendering. The first white light-emitting diodes (LEDs) were offered for sale in the autumn of 1996. Nichia made some of the first white LEDs which were based on blue LEDs with Ce:YAG phosphor. Ce:YAG is often grown using the Czochralski method.
== Clinical significance relevance == The protein UBC9 encoded by the UBE2I gene has been shown to be targeted by multiple viruses, including HIV and HPV. It has been hypothesized that these viruses hijack UBC9 to serve their own purposes.
In 1900, the German colonial administration of Nauru granted phosphate rights to British businessman John T. Arundel's Pacific Islands Company (PIC). The PIC was replaced by the Pacific Phosphate Company (PPC) in 1902, with German interests holding around one-third of the company's share capital. Production commenced in 1906, largely relying on indentured labour, with Australia and New Zealand as the primary markets. In 1914, following the outbreak of the First World War, the Australian Naval and Military Expeditionary Force occupied Nauru, with an agreement reached whereby the Australian military would assume administrative control of the island and the PPC would continue phosphate operations. Following the end of the war, Nauru was made a League of Nations mandate under the joint trusteeship of Australia, New Zealand and the United Kingdom, with Australia retaining administration of the island. In 1919, the three trustees signed the Nauru Island Agreement, which entitled them to the phosphate of Nauru through the British Phosphate Commissioners. They bought back all the assets of the PPC for more than 3.5 million pounds on 1 July 1920, and started to manage it directly on 1 January 1921, after a six-month transition period of PPC management. Most of PPC's former employees were retained by the BPC.
=== Br === Roscoe Brady (1923–2016). American biochemist at the National Institute of Neurological Disorders and Stroke, who identified many enzyme defects responsible for metabolic diseases. Member Natl. Acad. Sci. USA. Herman Branson (1914–1995). American physicist and biochemist who participated at Caltech in the discovery of the α-helix Sydney Brenner (1927–2019). South African biochemist at Cambridge, and later Berkeley, known for work on the genetic code and more recently for establishing Caenorhabditis elegans as a model organism. Nobel prize in Physiology or Medicine (2002) Roger Brent (b. 1955). American molecular biologist at the University of Washington known for work on gene regulation and systems biology Kenneth Breslauer (b. 1947). American biochemist at Rutgers University (born in Sweden of German parents), who has studied DNA damage and repair, including why certain mutations escape repair and result in cancer. Bernard Brodie (1907–1989). American biochemist and pharmacologist at the National Heart Institute, regarded as the founder of modern pharmacology. He studied drug metabolism and the mechanisms of drug effects. Member Natl. Acad. Sci. USA. Adrian John Brown FRS (1852–1920). British expert on brewing and malting at the University of Birmingham. He was a pioneer of enzyme kinetics and proposed an explanation of enzyme saturation. Patrick O. Brown (b. 1954). American biochemist at Stanford.
Sources: en.wikipedia.org
Late in the game, Freeman obtains a "long jump module" for the HEV suit, allowing him to increase the horizontal distance and speed of his jumps by crouching before jumping. The ability becomes particularly important in the Xen chapters, which introduce platforming-oriented challenges and low-gravity environments that require more precise movement. The Xen sections were subsequently criticized by some reviewers for their emphasis on jumping puzzles and less precise movement compared with the earlier portions of the game. The game also includes online multiplayer in individual and team-based deathmatch modes. Multiplayer uses the game's weapons and environments for competitive matches, providing an alternative to the single-player campaign's scripted progression. Contemporary coverage praised the multiplayer's weapon balance and level design, although its pace differed from faster contemporary shooters such as Quake. The combination of combat, puzzles, environmental interaction, and continuous scripted storytelling contributed to the game's reputation for immersion and interactivity. Contemporary reviewers repeatedly identified these qualities as major departures from the conventions of earlier first-person shooters, with GameSpot describing the game as a major step forward for the genre and other reviewers emphasizing its immersive presentation.
The industrial separation processes will be implemented stepwise by annular centrifugal contactors, developed for the first time at Argonne National Laboratory in the 1970s. The countercurrent process consists of the aqueous and organic phases moving continuously in opposite directions stage by stage. The two immiscible liquids enter each contactor unit, first contacted in the annular region between the housing and the spinning rotor and then centrifuged in the inner part of the unit. Two main ways are currently followed within the partitioning strategy: the heterogeneous and homogeneous recycling. All the first European research projects on hydrometallurgical partitioning started within the heterogeneous recycling, since none of the developed extracting agents were able to selectively extract actinides directly downstream of the PUREX process. This led research to develop first multi-stage and multi-cycle processes. A two-cycle process (DIAMide EXtraction + Selective ActiNide EXtraction) was developed for a selective actinide extraction downstream of a first co-extraction (DIAMEX) of actinides and lanthanides. The recent joint research projects point to develop innovative processes with a reduced number of cycles to directly extract minor actinides (americium and curium) from the PUREX raffinate in one cycle, either by a lipophilic extractant (1cycle-SANEX) or by a hydrophilic ligand (innovative-SANEX).
On June 7, after winning the election, Ford said that the "very first item" on his agenda would be to cancel the federal carbon tax and provincial cap-and-trade programs in order to prevent motorists from being "gouged at the pumps". According to a June 28, 2018 article in The Economist, Ontario, with "Canada's second-highest public debt per person and a growing budget deficit", Ford's "poleaxing of cap and trade" would result in C$2.8bn worth of pollution permits owned by companies that could result in lawsuits. The article said that Ontario would lose C$2bn a year from the sale of pollution permits under its cap-and-trade program, which represents 1.3% of Ontario's revenue. In November 2018, the Ford government announced that it was eliminating three provincial watchdog groups, including the Environmental Commissioner of Ontario (ECO), to cut costs. Then Environmental Commissioner of Ontario (ECO), Dianne Saxe, had just submitted her 4-volume, 339-page 2018 Environmental Protection Report, entitled "Back to Basics, to the Legislative Assembly of Ontario. Saxe was a "vocal critic" of the Ford government's "actions on climate change"—"their vow to fight a federal carbon tax, pulling out of more than 700 renewable energy contracts and moving to end the Ontario Green Energy Act." Bill 57, also known as the Restoring Trust, Transparency and Accountability Act transferred the Environmental Commissioner Officer's duties to the Auditor General of Ontario.
== Research Contributions == GeneDx researchers have contributed to peer-reviewed publications in major scientific and medical journals, generating critical data to expand access to genomic testing. In 2020, GeneDx researchers co-authored a study published in Nature analyzing data from 31,058 exome trios to identify 28 previously undescribed genes associated with developmental disorders, providing diagnoses for approximately 500 families. A 2021 study in JAMA, using data from GeneDx, found that exome sequencing identified pathogenic or likely pathogenic variants in 32.7% of pediatric patients with cerebral palsy, providing evidence to support genetic testing guidelines for the condition. In 2025, GeneDx collaborated with Seattle Children's and the University of Washington on the SeqFirst research program, which produced two landmark publications. The SeqFirst-Neo study, published in the American Journal of Human Genetics, found that applying broad exclusion criteria for rapid genome sequencing in NICUs increased the odds of a precise genetic diagnosis ninefold compared to conventional care, with 42% of diagnosed infants having been missed under standard protocols. A companion study published in The Journal of Pediatrics demonstrated that implementing rapid genome sequencing as a first-tier test in non-critical pediatric inpatient wards reduced the average time to a precise genetic diagnosis from 289 days to 13 days.
Tiagabine, sold under the brand name Gabitril, is an anticonvulsant medication which is used in the treatment of epilepsy. It is also used off-label in the treatment of insomnia and anxiety disorders. However, off-label use is discouraged as the drug has been associated with new-onset seizures in people without epilepsy. Tiagabine is taken orally. Side effects of tiagabine include dizziness, asthenia, non-specific nervousness, muscle tremors, diarrhea, depression, and emotional lability. The drug acts as a selective GABA transporter 1 (GAT-1) blocker or GABA reuptake inhibitor, and hence acts as an indirect GABA receptor agonist, increasing GABAergic signaling in the brain. It may increase activation of both GABAA and GABAB receptors. The effects of tiagabine on sleep resemble those of GABAA receptor agonists like gaboxadol and muscimol, primarily enhancing slow wave sleep, and differ from those of GABAA receptor positive allosteric modulators like benzodiazepines and Z drugs. The drug's elimination half-life is 4.5 to 9 hours, but can be shorter in people taking enzyme-inducing anticonvulsants. Tiagabine was discovered in 1988 and was introduced for medical use in 1997. Generic formulations have become available. The drug is not a controlled substance in the United States.
Sources: en.wikipedia.org
The lyophilized powder is normally kept at minus twenty degrees Celsius or colder. Solutions are held at refrigerator temperature or below and protected from light. Repeated freezing and thawing is avoided because it can promote aggregation or loss of activity.
Reverse-phase liquid chromatography is used to assess purity, and mass spectrometry confirms molecular mass. Together these two checks form the most widespread approach. Some laboratories add amino acid analysis for further verification.
Yes. The peptide is freely soluble in water and in aqueous buffers, so reconstitution does not require an organic solvent. Stock solutions are usually prepared in water or a mild buffer. Exact handling depends on the intended downstream application.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.